Outcome of children and adolescents with relapsed acute lymphoblastic leukaemia and non-response to salvage protocol therapy: A retrospective analysis of the ALL-REZ BFM Study Group

European Journal of Cancer

Volumn 47, Issue 1, 2011, Pages 90-97

  Von Stackelberg, Arend ^a   Völzke, Enrico ^b   Kühl, Jörn Sven ^a   Seeger, Karl ^a   Schrauder, André ^c   Escherich, Gabriele ^d   Henze, Günter ^a   Tallen, Gesche ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Schlossparkklinik ^*  (Germany)

^c Kiel and Lungen Clinic Grosshansdorf   (Germany)

^d UNIVERSITY OF HAMBURG   (Germany)

Author keywords

Chemotherapy; Childhood acute lymphoblastic leukaemia; Non response; Palliative care; Relapse

Indexed keywords

ANTINEOPLASTIC AGENT; GLUCOCORTICOID;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ARTICLE; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER RELAPSE; CANCER SURVIVAL; CHILD; CLINICAL PROTOCOL; DISEASE COURSE; DRUG MEGADOSE; FEMALE; HUMAN; LYMPHATIC LEUKEMIA; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PALLIATIVE THERAPY; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; SALVAGE THERAPY; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; PILOT PROJECTS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; QUALITY OF LIFE; RECURRENCE; RETROSPECTIVE STUDIES; SALVAGE THERAPY; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME; YOUNG ADULT;

EID: 78650414066     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2010.09.020     Document Type: Article

References (29)

1. M. Stanulla, and M. Schrappe Treatment of childhood acute lymphoblastic leukemia Semin Hematol 46 2009 52 63
2. G. Henze, and A. von Stackelberg Treatment of relapsed acute lymphoblastic leukemia C.H. Pui, Treatment of acute leukemias. New directions for clinical research 2002 Humana Press Totova, USA 199 219
3. C.H. Pui, J.T. Sandlund, and D. Pei Improved outcome for children with acute lymphoblastic leukemia: results of Total Therapy Study XIIIB at St. Jude Children's Research Hospital Blood 104 2004 2690 2696
4. G. Henze, R. Fengler, and S. Buchmann Initial results of a study of the treatment of children with ALL recurrences Onkologie 9 1986 92 95
5. G. Henze, R. Fengler, and R. Hartmann Six-year experience with a comprehensive approach to the treatment of recurrent childhood acute lymphoblastic leukemia (ALL-REZ BFM 85). A relapse study of the BFM Group Blood 78 1991 1166 1172
6. H.G. Einsiedel, A. von Stackelberg, and R. Hartmann Long-term outcome in children with relapsed ALL by risk-stratified salvage therapy. Results of trial ALL-REZ BFM 87 J Clin Oncol 23 2005 7942 7950
7. A. Von Stackelberg, R. Hartmann, and C. Buehrer High-dose compared with intermediate-dose methotrexate in children with a first relapse of acute lymphoblastic leukemia Blood 111 2008 2573 2580
8. G. Tallen, R. Ratei, and G. Mann Long-term outcome in children with relapsed acute lymphoblastic leukaemia after time-point and sit-of-relapse stratification and intensified short-course multidrug chemotherapy - results of trial ALL-REZ BFM 90 J Clin Oncol 28 2010 2339 2347
9. F.L. Johnson, E.D. Thomas, and B.S. Clark A comparison of marrow transplantation with chemotherapy for children with acute lymphoblastic leukemia in second or subsequent remission N Engl J Med 305 1981 846 851
10. B. Reismueller, A. Attarbaschi, and C. Peters Long-term outcome of initially homogeneously treated and relapsed childhood acute lymphoblastic leukaemia in Austria - a population-based report of the Austrian Berlin-Frankfurt-Muenster (BFM) Study Group Br J Haematol 144 2009 559 570
11. A. Von Stackelberg, D. Harms, and T. Klingebiel Improved outcome after relapse of childhood ALL - results of trial ALL-REZ BFM 95/96 Med Pediatr Oncol 39 2002 236
12. P.S. Gaynon, R.P. Qu, and R.J. Chappell Survival after relapse in childhood acute lymphoblastic leukemia: impact of site and time to first relapse - the Children's Cancer Group Experience Cancer 82 1998 1387 1395
13. S.E. Lawson, G. Harrison, and S. Richards The UK experience in treating relapsed childhood acute lymphoblastic leukaemia: a report on the Medical Research Council UKALLR1 study Br J Haematol 108 2000 531 543
14. G. Henze, A.G. Agthe, and A. Neuendank Tailored therapy for relapsed or refractory childhood acute lymphoblastic leukemia Leukemia 9 1995 538
15. W. Dörffel, R. Hartmann, and S. Schober Drug resistance testing as a basis for tailored therapy in children with refractory or relapsed acute lymphoblastic leukemia G.J. Kaspers, Drug resistance in leukemia and lymphoma 1995 Harwood Academic Publishers 353 357
16. Klumper E, Pieters R, Kaspers GJL, et al. Treatment of children with poor prognosis relapsed acute lymphoblastic leukemia based on individual drug resistance profiles: procedure. In Kaspers GJ et al., editors. Drug resistance in leukemia and lymphoma. Harwood Academic Publishers; 1993. p. 345-51.
17. E.L. Kaplan, and P. Meier Nonparametric estimation from incomplete observations J Am Stat Assoc 53 1958 457 481
18. B. Beyermann, H.P. Adams, and G. Henze Philadelphia chromosome in relapsed childhood acute lymphoblastic leukaemia: a matched-pair analysis. The Berlin-Frankfurt-Munster Study Group J Clin Oncol 15 1997 2231 2237
19. G. Fleischhack, N. Graf, and C. Hasan IDA-FLAG (idarubicin, fludarabine, high dosage cytarabine and G-CSF) - an effective therapy regimen in treatment of recurrent acute myelocytic leukemia in children and adolescents. Initial results of a pilot study Klin Padiatr 208 1996 229 235
20. U. Creutzig, M. Zimmermann, and J. Ritter Treatment strategies and long-term results in paediatric patients treated in four consecutive AML-BFM trials Leukemia 19 2005 2030 2042
21. D. Niethammer, T. Klingebiel, and W. Ebell Which children benefit from bone marrow transplant? Bone Marrow Transplant 18 1996 43 46
22. R. Dopfer, G. Henze, and C. Bender-Götze Allogenic bone marrow transplantation for childhood acute lymphoblastic leukemia in second remission after intensive primary and relapse therapy according to the BFM- and CoALL-protocols: results of the german cooperative study Blood 78 1991 2780 2784
23. A. Borgmann, E. Baumgarten, and H. Schmid Allogeneic bone marrow transplantation for a subset of children with acute lymphoblastic leukemia in third remission: a conceivable alternative? Bone Marrow Transplant 20 1997 939 944
24. H. Schmid, U. Schenck, R. Hartmann, A. Borgmann, and G. Henze Allogeneic BMT vs. chemotherapy in late bone marrow relapsed childhood non-T/non-B ALL: results of the ALL relapse studies Bone Marrow Transplant 18 1996 228 230
25. J. Wolfe, N. Klar, and E.G. Holcombe Understanding of prognosis among parents of children who died of cancer. Impact on treatment goals and integration of palliative care JAMA 284 2000 2469 2475
26. T. Hechler, M. Blankenburg, and S.J. Friedrichsdorf Parents' perspective on symptoms, quality of life, characteristics of death and end-of-life decisions for children dying from cancer Klin Padiatr 220 2008 166 174
27. P. Bader, H. Kreyenberg, and G.H. Henze Prognostic value of minimal residual disease quantification before allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia: the ALL-REZ BFM Study Group J Clin Oncol 27 2009 377 384
28. N. Hijiya, P. Gaynon, and E. Barry Acute leukemias. A multi-center phase I study of clofarabine, etoposide and cyclophosphamide in combination in pediatric patients with refractory or relapsed acute leukemia Leukemia 23 2009 2259 2264
29. S.L. Berg, S.M. Blaney, and M. Devidas Phase II study of nelarabine (compound 506U78) in children and young adults with refractory T-cell malignancies: a report from the children's oncology group J Clin Oncol 23 2005 3376 3382